J&J's Schizophrenia Drug Wins FDA Priority Review

Source: Wall Street Journal

May 19, 2015

The U.S. FDA has granted priority review to J&J's Janssen Pharmaceuticals' new drug application for antipsychotic Invega Trinza.

Invega Trinza is a three-month injection administered four times a year, offering the longest dosing interval available for schizophrenia patients. Patients must first be treated with Invega Sustenna, a once-monthly injection, for at least four months before undergoing treatment.

According to a study published by the companies in March, 93% of patients in a long-term maintenance trial treated with Invega Trinza didn't experience a significant return of schizophrenia symptoms.

Read the WSJ article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments